x

Intellia Therapeutics and Regeneron Pharmaceuticals have announced a licensing and collaboration agreement to advance CRISPR/Cas gene editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of the CRISPR/Cas platform. Read More..

OUR MISSION

Developing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

LEARN MORE